Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery

By sjmartinez • November 20, 2022

Phung MT, Webb PM, DeFazio A, Fereday S, Lee AW, Bowtell DDL, Fasching PA, Goode EL, Goodman MT, Karlan BY, Lester J, Matsuo K, Modugno F, Brenton JD, Van Gorp T, Pharoah PDP, Schildkraut JM, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, McKinnon Deurloo C, Terry KL, Hanley GE, Pike MC, Berchuck A, Ramus SJ, Pearce CL; Ovarian Cancer Association Consortium. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecol Oncol. 2022 Nov 16;168:68-75. doi: 10.1016/j.ygyno.2022.10.018. Epub ahead of print. PMID: 36401943.

Tags: Hematology/Oncology, Lifestyle, ovarian cancer, Primary cytoreductive surgery, Publications, Residual disease

Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors

Sarkar S, Sedrak MS, Carroll JE, Schechter C, Muss HB, Mandelblatt JS. Chemotherapy-Induced Biological Age Acceleration and Lifetime Outcomes in Breast Cancer Survivors. JAMA Netw[...]

Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy

Li YR, Zhu Y, Yu Y, Kramer A, Shao Z, Chen Y, Shen X, Zhang C, Ma N, Zhao A, Ochoa CJ, DiBernardo GA, Yuen[...]

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

Paulson S, Ikeda M, Shen L, Stein A, Macarulla T, Milella M, Golan T, Wainberg Z, Taieb J, Wang L, Polydoros F, Abecunas C, López[...]